AC Immune (ACIU) Other Non-Current Assets (2014 - 2026)
AC Immune's (ACIU) quarterly Other Non-Current Assets came in at $747.0 million in Q1 2026, up 114712.68% year-on-year from N/an in Q1 2025, and up 2.24% on a QoQ basis from $730.7 million in Q4 2025.
AC Immune (ACIU) Other Non-Current Assets (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has 13 years of Other Non-Current Assets data on file, last reported at $747.0 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 114712.68% year-over-year to $747.0 million in Q1 2026; TTM through Mar 2026 was $747.0 million, a 114712.68% increase from a year earlier, with the FY2025 full-year figure at $704.4 million, up 148587.38% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $747.0 million, up from $730.7 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for ACIU reached as high as $747.0 million in Q1 2026 and fell as low as $373799.8 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $156.4 million across 5 years, with a median of $478996.0 in 2024.
- Across the five-year window, Other Non-Current Assets tumbled 99.91% in 2022 and soared 154139.91% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $374725.9 in 2022, then jumped by 108506.04% to $407.0 million in 2023, then plunged by 99.88% to $473731.6 in 2024, then surged by 154139.91% to $730.7 million in 2025, then rose by 2.24% to $747.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $747.0 million in Q1 2026, $730.7 million in Q4 2025, and $730064.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | AC Immune | 225.68 Mn | 225.68 Mn | - | 747.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 747.05 Mn |
| Dec 31, 2025 | 730.68 Mn |
| Sep 30, 2025 | 730,063.96 |
| Jun 30, 2025 | 705,407.89 |
| Mar 31, 2025 | 650,666.56 |
| Dec 31, 2024 | 473,731.57 |
| Sep 30, 2024 | 478,996.01 |
| Jun 30, 2024 | 458,904.30 |
| Mar 31, 2024 | 475,458.16 |
| Dec 31, 2023 | 406.97 Mn |
| Sep 30, 2023 | 408,707.08 |
| Jun 30, 2023 | 401,495.37 |
| Mar 31, 2023 | 390,299.69 |
| Dec 31, 2022 | 374,725.91 |
| Sep 30, 2022 | 373,799.85 |
| Jun 30, 2022 | 374.82 Mn |
| Mar 31, 2022 | 393.06 Mn |
| Dec 31, 2021 | 393.67 Mn |
| Sep 30, 2021 | 395.35 Mn |
| Jun 30, 2021 | 398.08 Mn |